Aim: This study quantified the cost of major head and neck cancer (HNC) surgery.
Methods: Consecutive patients undergoing major HNC surgery between July 2007 and June 2012 were identified from our head and neck database. Patient demographics, tumour type, site, stage and types of resection and reconstruction, length of stay and surgical complications occurring within six months of initial surgery were retrospectively analysed. The actual cost of initial surgical treatment and hospital income were calculated.
Results: Two hundred and forty-five patients underwent major HNC surgery, most commonly for mucosal squamous cell carcinoma (SCC) and metastatic and/or locally advanced cutaneous SCC. Neck dissection and parotidectomy were the commonest resection procedures and free flaps the commonest reconstructive procedures performed. Forty-two patients developed surgical complications within six months of the initial major HNC surgery. Over the five-year period, surgery cost a total of NZ$5,130,639.00, averaging NZ$20,941.38 per patient, not including costs such as incidentals, while the hospital received NZ$4,976,559.61 averaging NZ$20,229.91/patient. On average, oral cavity cancer, metastatic and/or locally advanced skin cancer, and skull base cancer cost NZ$22,694.72/patient, NZ$17,373.64/patient and NZ$47,295.95/patient, respectively.
Conclusion: Calculated hospital income marginally covered the actual cost of major HNC surgery, which places substantial financial burden on the hospital. The anatomic site of the tumour determines the cost of treatment.
Download full-text PDF |
Source |
---|
Asian Pac J Cancer Prev
January 2025
Department of Molecular Biology & Genetics, Krishna Institute of Allied Sciences, Krishna Vishwa Vidyapeeth "Deemed to be University", Taluka-Karad, Dist- Satara, Pin-415 539, (Maharashtra) India.
Background: In this study we explored the association of polymorphisms of glutathione s transferase gene including GSTM1, GSTT1 and GSTP1 with adverse acute normal tissue reactions resulted from radiotherapy in HNC patients. We assessed the association of GSTM1 and GSTT1 null genotypes and Ile105Val of exon-5 and Ala114Val of exon-6 of GSTP1 gene polymorphisms with the risk of acute skin toxicity reactions after therapeutic radiotherapy in HNC patients.
Methods: Four hundred HNC patients administered with Intensity modulated radiation therapy were enrolled in this study for the evaluation of radiotherapy associated toxicity reactions.
Laryngoscope
January 2025
Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, U.S.A.
Objectives: To investigate the consistency of associations between modified frailty index-5 (mFI-5) and postoperative adverse outcomes in head and neck cancer (HNC) reconstruction.
Methods: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database from 2017 to 2022 was utilized to identify HNC patients undergoing locoregional or microvascular free tissue transfers. Kaplan-Meier estimates and multivariable Cox regression analyses were utilized to compare risk of infections, bleeding, readmissions, reoperations, major adverse cardiovascular events (MACE), and mortality within the first postoperative month for each mFI-5 score with mFI-5 = 0 as reference.
Clin Exp Otorhinolaryngol
January 2025
Department of Otorhinolaryngology - Head and Neck Surgery, Konkuk University College of Medicine, Seoul, South Korea.
Objectives: We aimed to calculate the age-adjusted incidence rate of head and neck cancer (HNC) in South Korea from 1999 to 2020 and investigate the incidence trend of HNC excluding the effect of population aging.
Methods: Data were obtained from the Cancer Registration Statistics Program. All 12 types of HNCs were analyzed.
Exp Hematol Oncol
January 2025
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Background: Radiotherapy is the primary treatment modality for most head and neck cancers (HNCs). Despite the addition of chemotherapy to radiotherapy to enhance its tumoricidal effects, almost a third of HNC patients suffer from locoregional relapses. Salvage therapy options for such recurrences are limited and often suboptimal, partly owing to divergent tumor and microenvironmental factors underpinning radioresistance.
View Article and Find Full Text PDFCells
December 2024
Radiotherapy Department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.
Definitive chemoradiotherapy (CRT) is a cornerstone of treatment for locoregionally advanced head and neck cancer (HNC). Research is ongoing on how to improve the tumor response to treatment and limit normal tissue toxicity. A major limitation in that regard is the growing occurrence of intrinsic or acquired treatment resistance in advanced cases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!